Skip to the main content

Professional paper

The Problem of Informed Consent of Persons with Neurocognitive Disorders in Clinical Investigations

Suzana Uzun ; University Psychiatric Hospital Vrapče, Zagreb, Josip Juraj Strossmayer University in Osijek, School of Medicine, Osijek;
Oliver Kozumplik ; University Psychiatric Hospital Vrapče, Zagreb, Josip Juraj Strossmayer University in Osijek, School of Medicine, Osijek;
Dubravka Kalinić ; University of Zagreb, School of Medicine, Zagreb
Nela Pivac ; Institute Ruđer Bošković, Zagreb, Croatia
Ninoslav Mimica ; University Psychiatric Hospital Vrapče, Zagreb, University of Zagreb, School of Medicine, Zagreb


Full text: croatian pdf 207 Kb

page 202-208

downloads: 315

cite

Full text: english pdf 207 Kb

page 202-208

downloads: 813

cite


Abstract

From the beginning of the millennium showed that the prevalence of Alzheimer’s disease was at 24.3 million of patients globally, but also anticipated a significant increase of the number of new cases of
dementia, which are currently at 4.6 million. Currently, based on estimates from the ADI (Alzheimer Disease International), a head association that aggregates data 80 national Alzheimer organizations, it is apparent that there are more than 47 million persons with dementia in the world today. However, what is concerning is the statement that this number will continue to grow progressively. Biomedical investigations are an invaluable (and the only) source of new knowledge, thanks to which significant progress has been achieved in medicine during previous century and continues to be achieved
today. In the field of clinical investigations, persons with dementia represent a vulnerable group. The legal representative of the person with dementia cannot give consent for participation in clinical investigation, which represents a potentially limiting factor for clinical investigations that include persons with dementia. In psychiatry, the evaluation of patient competence for giving informed consent is necessary. Given the specificity of mental disorders, this evaluation is necessary in order to protect the patient and their choice of medical procedure as well as to avoid misuse in everyday clinical practice.

Keywords

Alzheimer’s disease; Dementia; Ethics; Clinical investigation; Inform consent

Hrčak ID:

190350

URI

https://hrcak.srce.hr/190350

Publication date:

11.9.2017.

Article data in other languages: croatian

Visits: 2.413 *